| Joya Sahu, MD | |
|
930 Madison Ave Ste 890, Memphis, TN 38103-3413 | |
| (901) 866-8834 | |
| (901) 302-2834 |
| Full Name | Joya Sahu |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 18 Years |
| Location | 930 Madison Ave Ste 890, Memphis, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548471071 | NPI | - | NPPES |
| 102612614 | Medicaid | PA | |
| 0266655 | Medicaid | NJ | |
| MD.37771 | Other | AL | AL MD |
| Q089003 | Medicaid | TN |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southeastern Dermatology Group Pa | 9931277233 | 42 |
News Archive
Human arteries - some smaller than a strand of hair - stiffen as a person ages. This stiffening is a factor in cardiovascular disease, the leading cause of death in the United States, because it contributes to the circulatory complications in disorders such as high blood pressure and diabetes. University of Missouri researchers have now used advanced 3-D microscopic imaging technology to identify and monitor the proteins involved in this stiffening process.
A new report from Citigroup Global Markets forecasts difficult times ahead for hospitals and other related businesses that rely on government spending.
Affymax, Inc. today announced that it has instituted a quiet period to curtail discussions with the investor community and the media in connection with the analysis of Phase 3 results for the investigational drug, Hematide, in four clinical trials (PEARL 1, PEARL 2, EMERALD 1 and EMERALD 2) which evaluated Hematide for the treatment of anemia in chronic renal failure patients.
ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.
TaiGen Biotechnology Company, Limited today announced that the U.S. Food and Drug Administration has granted nemonoxacin (Taigexyn) Qualified Infectious Disease Product and Fast Track designations for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
› Verified 7 days ago
| Entity Name | Southeastern Dermatology Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518972231 PECOS PAC ID: 9931277233 Enrollment ID: O20110628000133 |
News Archive
Human arteries - some smaller than a strand of hair - stiffen as a person ages. This stiffening is a factor in cardiovascular disease, the leading cause of death in the United States, because it contributes to the circulatory complications in disorders such as high blood pressure and diabetes. University of Missouri researchers have now used advanced 3-D microscopic imaging technology to identify and monitor the proteins involved in this stiffening process.
A new report from Citigroup Global Markets forecasts difficult times ahead for hospitals and other related businesses that rely on government spending.
Affymax, Inc. today announced that it has instituted a quiet period to curtail discussions with the investor community and the media in connection with the analysis of Phase 3 results for the investigational drug, Hematide, in four clinical trials (PEARL 1, PEARL 2, EMERALD 1 and EMERALD 2) which evaluated Hematide for the treatment of anemia in chronic renal failure patients.
ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.
TaiGen Biotechnology Company, Limited today announced that the U.S. Food and Drug Administration has granted nemonoxacin (Taigexyn) Qualified Infectious Disease Product and Fast Track designations for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joya Sahu, MD 1407 Union Ave Ste 700, Memphis, TN 38104-3641 Ph: () - | Joya Sahu, MD 930 Madison Ave Ste 890, Memphis, TN 38103-3413 Ph: (901) 866-8834 |
News Archive
Human arteries - some smaller than a strand of hair - stiffen as a person ages. This stiffening is a factor in cardiovascular disease, the leading cause of death in the United States, because it contributes to the circulatory complications in disorders such as high blood pressure and diabetes. University of Missouri researchers have now used advanced 3-D microscopic imaging technology to identify and monitor the proteins involved in this stiffening process.
A new report from Citigroup Global Markets forecasts difficult times ahead for hospitals and other related businesses that rely on government spending.
Affymax, Inc. today announced that it has instituted a quiet period to curtail discussions with the investor community and the media in connection with the analysis of Phase 3 results for the investigational drug, Hematide, in four clinical trials (PEARL 1, PEARL 2, EMERALD 1 and EMERALD 2) which evaluated Hematide for the treatment of anemia in chronic renal failure patients.
ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.
TaiGen Biotechnology Company, Limited today announced that the U.S. Food and Drug Administration has granted nemonoxacin (Taigexyn) Qualified Infectious Disease Product and Fast Track designations for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
› Verified 7 days ago
Dr. Emily T. Overholser, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1455 Union Ave, Memphis, TN 38104 Phone: 901-726-6655 Fax: 901-726-9056 | |
Dr. Maureen Poh, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1910 Nonconnah Blvd, Suite 120, Memphis, TN 38132 Phone: 901-448-2300 Fax: 901-448-6657 | |
Dr. Robert B Skinner, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1910 Nonconnah Blvd, Suite 120, Memphis, TN 38132 Phone: 901-448-2300 Fax: 901-448-6657 | |
Dr. Mark Harris Tanenbaum, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 760 Brookhaven Circle, Memphis, TN 38117 Phone: 901-761-0500 Fax: 901-761-0537 | |
Dr. Alan Harris Tanenbaum, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 760 E Brookhaven Cir, Memphis, TN 38117 Phone: 901-761-0500 | |
Dr. Courtney Stroupe Woodmansee, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1455 Union Ave, Memphis, TN 38104 Phone: 901-726-6655 | |
Dr. Srinidhi Reddy Pulusani, MD Dermatology Medicare: Medicare Enrolled Practice Location: 930 Madison Ave Ste 801, Memphis, TN 38103 Phone: 901-866-8805 Fax: 901-302-2790 |